GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » Cyclically Adjusted PS Ratio

Reshape Lifesciences (STU:24O0) Cyclically Adjusted PS Ratio : (As of May. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Reshape Lifesciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Reshape Lifesciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Cyclically Adjusted PS Ratio Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.07 0.01 -

Reshape Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reshape Lifesciences's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Reshape Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Cyclically Adjusted PS Ratio falls into.



Reshape Lifesciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Reshape Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Reshape Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.518/131.7762*131.7762
=0.518

Current CPI (Mar. 2024) = 131.7762.

Reshape Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.707 100.684 0.925
201509 0.410 100.392 0.538
201512 1.734 99.792 2.290
201603 32.500 100.470 42.627
201606 82.000 101.688 106.263
201609 24.091 101.861 31.166
201612 12.273 101.863 15.877
201703 0.319 102.862 0.409
201706 8.300 103.349 10.583
201709 23.231 104.136 29.397
201712 4.923 104.011 6.237
201803 941.667 105.290 1,178.553
201806 75.000 106.317 92.960
201809 1.400 106.507 1.732
201812 5.425 105.998 6.744
201903 2,720.000 107.251 3,342.001
201906 1,969.000 108.070 2,400.930
201909 638.400 108.329 776.575
201912 9.298 108.420 11.301
202003 18.423 108.902 22.293
202006 10.949 108.767 13.265
202009 38.709 109.815 46.450
202012 33.367 109.897 40.010
202103 34.253 111.754 40.390
202106 32.187 114.631 37.001
202109 9.216 115.734 10.493
202112 7.790 117.630 8.727
202203 5.973 121.301 6.489
202206 7.088 125.017 7.471
202209 6.266 125.227 6.594
202212 6.016 125.222 6.331
202303 1.251 127.348 1.295
202306 0.640 128.729 0.655
202309 0.585 129.860 0.594
202312 0.526 129.419 0.536
202403 0.518 131.776 0.518

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Reshape Lifesciences  (STU:24O0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Reshape Lifesciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (STU:24O0) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines